(R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide
- PMID: 11498713
- DOI: 10.1007/s002130100730
(R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide
Abstract
Rationale and objectives: (R)-methanandamide (AM-356), a metabolically more stable chiral analog of the endocannabinoid ligand anandamide, was used as a representative of fatty acid ethanolamide CB1 receptor ligands to characterize the discriminative stimulus functions of anandamides.
Methods: Rats discriminated between 10 mg/kg (R)-methanandamide and vehicle administered IP 15 min prior to session onset. Another group of rats was initially trained to discriminate between 3 mg/kg Delta9-THC and vehicle given IP 30 min prior to session onset; for anandamide testing, the animals were retrained with 1.8 and 5.6 mg/kg Delta9-THC. A two lever operant methodology (FR10) was used.
Results: Delta9-THC was more potent than (R)-methanandamide at both 15 and 30 min post-injection, irrespective of the training drug used. Additional tests with 10 and 18 mg/kg (R)-methanandamide suggested that the effects were declining by 1 h. The cannabinoid antagonist SR 141716 (0.3 and 1 mg/kg) produced rightward shifts in the Delta9-THC dose-response curve for Delta9-THC-appropriate responding and for (R)-methanandamide-appropriate responding (surmountable antagonism). SR-141716 (0.3 and 1 mg/kg) antagonized the ability of (R)-methanandamide to occasion either Delta9-THC-appropriate responding or (R)-methanandamide-appropriate responding. This antagonism was surmountable only at a dose of 0.3 mg/kg SR-1421716 in the (R)-methanandamide-trained rats. SR-141716 did not antagonize the rate-decreasing effects of (R)-methanandamide in either the Delta9-THC or the (R)-methanandamide trained rats. Response suppression precluded testing doses higher than 30 mg/kg (R)-methanandamide. Tests with SR-141716 (1 and 10 mg/kg) alone resulted in <3% Delta9-THC-appropriate responding. With 10 mg/kg SR-141716, response rate was significantly lower as compared to the rate observed during a vehicle test. Tests with anandamide (10 and 18 mg/kg) resulted in 41% and 85% (R)-methanandamide-appropriate responding at a 3-min pre-treatment time, but in a maximum of 15% (R)-methanandamide-appropriate responding at a longer (15 min) pre-treatment time. In the Delta9-THC (1.8 and 5.6 mg/kg) trained rats, anandamide never produced more than about 20% Delta9-THC-appropriate responding.
Conclusion: The results add to a growing body of evidence indicating that there are both similarities and dissimilarities between classical cannabinoids such as THC and endogenous fatty acid ethanolamides.
Similar articles
-
Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.Psychopharmacology (Berl). 2009 Apr;203(2):219-28. doi: 10.1007/s00213-008-1230-8. Epub 2008 Jul 1. Psychopharmacology (Berl). 2009. PMID: 18592221 Free PMC article.
-
Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with Delta9-THC or (R)-methanandamide (AM-356).Psychopharmacology (Berl). 2006 Oct;188(3):315-23. doi: 10.1007/s00213-006-0517-x. Epub 2006 Sep 5. Psychopharmacology (Berl). 2006. PMID: 16953384
-
Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats.Psychopharmacology (Berl). 2006 Jan;184(1):36-45. doi: 10.1007/s00213-005-0225-y. Epub 2005 Nov 24. Psychopharmacology (Berl). 2006. PMID: 16307294
-
Cannabis: discrimination of "internal bliss"?Pharmacol Biochem Behav. 1999 Oct;64(2):257-60. doi: 10.1016/s0091-3057(99)00059-3. Pharmacol Biochem Behav. 1999. PMID: 10515300 Review.
-
Cannabinoid receptors and their endogenous agonist, anandamide.Neurochem Res. 1998 May;23(5):575-81. doi: 10.1023/a:1022418217479. Neurochem Res. 1998. PMID: 9566594 Review.
Cited by
-
Cannabinoid CB1 Discrimination: Effects of Endocannabinoids and Catabolic Enzyme Inhibitors.J Pharmacol Exp Ther. 2017 Dec;363(3):314-323. doi: 10.1124/jpet.117.244392. Epub 2017 Sep 25. J Pharmacol Exp Ther. 2017. PMID: 28947487 Free PMC article.
-
Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB1 receptor-mediated discriminative stimulus in mice.Neuropharmacology. 2017 Oct;125:80-86. doi: 10.1016/j.neuropharm.2017.06.032. Epub 2017 Jun 30. Neuropharmacology. 2017. PMID: 28673548 Free PMC article.
-
Apparent CB1 Receptor Rimonabant Affinity Estimates: Combination with THC and Synthetic Cannabinoids in the Mouse In Vivo Triad Model.J Pharmacol Exp Ther. 2017 Jul;362(1):210-218. doi: 10.1124/jpet.117.240192. Epub 2017 Apr 25. J Pharmacol Exp Ther. 2017. PMID: 28442584 Free PMC article.
-
Discriminative Stimulus Properties of Phytocannabinoids, Endocannabinoids, and Synthetic Cannabinoids.Curr Top Behav Neurosci. 2018;39:153-173. doi: 10.1007/7854_2016_24. Curr Top Behav Neurosci. 2018. PMID: 27278640 Review.
-
Preclinical studies on the reinforcing effects of cannabinoids. A tribute to the scientific research of Dr. Steve Goldberg.Psychopharmacology (Berl). 2016 May;233(10):1845-66. doi: 10.1007/s00213-016-4244-7. Epub 2016 Mar 30. Psychopharmacology (Berl). 2016. PMID: 27026633 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials